Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 568

1.
2.

Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.

O'Neill J, Schuff N, Marks WJ Jr, Feiwell R, Aminoff MJ, Weiner MW.

Mov Disord. 2002 Sep;17(5):917-27.

PMID:
12360540
3.

Diminished subcortical nuclei volumes in Parkinson's disease by MR imaging.

Lisanby SH, McDonald WM, Massey EW, Doraiswamy PM, Rozear M, Boyko OB, Krishnan KR, Nemeroff C.

J Neural Transm Suppl. 1993;40:13-21.

PMID:
8294897
4.

Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature.

Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U.

Brain. 2010 Nov;133(11):3423-33. doi: 10.1093/brain/awq212. Epub 2010 Aug 23.

PMID:
20736190
5.

MRI atrophy parameters related to cognitive and motor impairment in Parkinson's disease.

Alegret M, Junqué C, Pueyo R, Valldeoriola F, Vendrell P, Tolosa E, Mercader JM.

Neurologia. 2001 Feb;16(2):63-9.

PMID:
11257931
6.

Signal alterations of the basal ganglia in the differential diagnosis of Parkinson's disease: a retrospective case-controlled MRI data bank analysis.

Jesse S, Kassubek J, Müller HP, Ludolph AC, Unrath A.

BMC Neurol. 2012 Dec 29;12:163. doi: 10.1186/1471-2377-12-163.

7.

Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease.

Schocke MF, Seppi K, Esterhammer R, Kremser C, Mair KJ, Czermak BV, Jaschke W, Poewe W, Wenning GK.

Neuroimage. 2004 Apr;21(4):1443-51.

PMID:
15050569
8.

T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.

Atasoy HT, Nuyan O, Tunc T, Yorubulut M, Unal AE, Inan LE.

Neurol India. 2004 Sep;52(3):332-7.

9.

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD.

Brain. 1991 Aug;114 ( Pt 4):1953-75.

PMID:
1832073
10.

Basal ganglia iron content in Parkinson's disease measured with magnetic resonance.

Ye FQ, Allen PS, Martin WR.

Mov Disord. 1996 May;11(3):243-9.

PMID:
8723139
11.

Increased intracranial volume in Parkinson's disease.

Krabbe K, Karlsborg M, Hansen A, Werdelin L, Mehlsen J, Larsson HB, Paulson OB.

J Neurol Sci. 2005 Dec 15;239(1):45-52. Epub 2005 Oct 11.

PMID:
16225890
12.

Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.

Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP.

Neuroscience. 1988 May;25(2):419-38.

PMID:
2456487
13.

Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy.

Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, Boesch S, Jaschke W, Poewe W, Wenning GK.

Neurology. 2003 Mar 25;60(6):922-7.

PMID:
12654954
14.

Magnetic resonance imaging-based morphometry and landmark correlation of basal ganglia nuclei.

Zhu XL, Hamel W, Schrader B, Weinert D, Hedderich J, Herzog J, Volkmann J, Deuschl G, Müller D, Mehdorn HM.

Acta Neurochir (Wien). 2002 Oct;144(10):959-69; discussion 968-9.

PMID:
12382123
15.

T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.

Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP.

Mov Disord. 2011 Aug 1;26(9):1633-8. doi: 10.1002/mds.23722. Epub 2011 Apr 12. Erratum in: Mov Disord. 2012 Feb;27(2):335.

PMID:
21491489
16.

Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.

Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, Zeng M, Zhong C.

Brain. 2011 Jan;134(Pt 1):50-8. doi: 10.1093/brain/awq319. Epub 2010 Nov 24.

PMID:
21109502
17.

Increased basal ganglia iron in striatonigral degeneration: in vivo estimation with magnetic resonance.

Martin WR, Roberts TE, Ye FQ, Allen PS.

Can J Neurol Sci. 1998 Feb;25(1):44-7.

PMID:
9532280
18.

T2 relaxation time in patients with Parkinson's disease.

Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M.

Neurology. 1993 Apr;43(4):697-700.

PMID:
8469325
19.

Evaluation of basal ganglia haemodynamic changes with perfusion-weighted magnetic resonance imaging in patients with Parkinson's disease.

Gaudiello F, Garaci FG, Marziali S, Ludovici A, Brusa L, Stanzione P, Floris R, Simonetti G.

Radiol Med. 2006 Mar;111(2):284-90. English, Italian.

PMID:
16671385
20.

Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease.

Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, Chazot G.

Arch Neurol. 1995 Jun;52(6):583-8.

PMID:
7763206

Supplemental Content

Support Center